梅花生物
(600873)
| 流通市值：222.94亿 | | | 总市值：222.94亿 |
| 流通股本：28.04亿 | | | 总股本：28.04亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 12,235,095,339.54 | 5,985,631,650.28 | 24,208,675,106.7 | 18,215,447,345 |
| 营业总成本 | 11,604,845,391.33 | 5,882,482,412.56 | 21,603,821,463.14 | 15,834,727,996.42 |
| 其他经营收益 | | | | |
| 营业利润 | 818,777,786.37 | 139,273,827.89 | 2,909,062,330.41 | 2,658,930,345.81 |
| 利润总额 | 830,402,774.44 | 154,316,792.71 | 3,729,699,988.92 | 3,442,504,529.33 |
| 净利润 | 661,862,706.23 | 117,920,964.07 | 3,280,879,912.1 | 3,025,092,355.05 |
| 每股收益 | | | | |
| 其他综合收益 | -99,766,392.99 | -49,472,357.85 | -104,215,210.75 | -80,102,163.16 |
| 综合收益总额 | 562,096,313.24 | 68,448,606.22 | 3,176,664,701.35 | 2,944,990,191.89 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 10,758,805,452.72 | 9,819,233,165.2 | 9,687,798,652.21 | 9,862,310,001.34 |
| 非流动资产: | | | | |
| 非流动资产合计 | 16,026,619,983.58 | 16,149,436,172.91 | 16,228,178,073.17 | 16,129,029,901.76 |
| 资产总计 | 26,785,425,436.3 | 25,968,669,338.11 | 25,915,976,725.38 | 25,991,339,903.1 |
| 流动负债: | | | | |
| 流动负债合计 | 8,787,667,371.57 | 7,081,646,179.01 | 7,263,114,490.32 | 7,646,482,274.56 |
| 非流动负债: | | | | |
| 非流动负债合计 | 2,326,843,634.6 | 2,469,812,717.56 | 2,305,291,819.5 | 2,229,022,859.09 |
| 负债合计 | 11,114,511,006.17 | 9,551,458,896.57 | 9,568,406,309.82 | 9,875,505,133.65 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 15,670,914,430.13 | 16,417,210,441.54 | 16,347,570,415.56 | 16,115,834,769.45 |
| 股东权益合计 | 15,670,914,430.13 | 16,417,210,441.54 | 16,347,570,415.56 | 16,115,834,769.45 |
| 负债和股东权益合计 | 26,785,425,436.3 | 25,968,669,338.11 | 25,915,976,725.38 | 25,991,339,903.1 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 13,502,028,923.54 | 6,719,761,329.84 | 27,163,735,035.37 | 20,713,725,008.57 |
| 经营活动现金流出小计 | 13,112,888,839.52 | 7,875,318,818.39 | 23,154,475,389.14 | 16,002,565,010.23 |
| 经营活动产生的现金流量净额 | 389,140,084.02 | -1,155,557,488.55 | 4,009,259,646.23 | 4,711,159,998.34 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 447,137,390.01 | 257,351,780.99 | 142,369,783.85 | 69,029,336.35 |
| 投资活动现金流出小计 | 2,222,286,719.06 | 784,256,541.63 | 3,286,550,501.89 | 3,643,711,406.98 |
| 投资活动产生的现金流量净额 | -1,775,149,329.05 | -526,904,760.64 | -3,144,180,718.04 | -3,574,682,070.63 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 2,260,768,019.92 | 1,257,639,585.33 | 5,935,340,781.92 | 4,743,961,248.87 |
| 筹资活动现金流出小计 | 2,238,141,424.44 | 1,160,628,542.1 | 6,942,872,700.16 | 5,785,108,571.33 |
| 筹资活动产生的现金流量净额 | 22,626,595.48 | 97,011,043.23 | -1,007,531,918.24 | -1,041,147,322.46 |
| 汇率变动对现金及现金等价物的影响 | -61,143,692.42 | -31,457,118.43 | 17,029,234.7 | 25,528,099.8 |
| 现金及现金等价物净增加额 | -1,424,526,341.97 | -1,616,908,324.39 | -125,423,755.35 | 120,858,705.05 |
| 期末现金及现金等价物余额 | 2,581,909,504.82 | 2,389,527,522.4 | 4,006,435,846.79 | 4,252,718,307.19 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | -1,424,526,341.97 | - | -125,423,755.35 | - |
最新报告期：2026-05-17| 研究机构 | 分析师 | 预测每股收益(元) | 更新日 |
| 2026年 | 2027年 | 2028年 |
| 申万宏源 | 周超,宋涛 | 0.75 | 0.89 | 1.00 | 2026-05-17 |